Home » Stocks » Adial Pharmaceuticals

Adial Pharmaceuticals, Inc. (ADIL)

Stock Price: $1.32 USD -0.06 (-4.35%)
Updated Jul 14, 2020 1:22 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 17.75M
Revenue (ttm) n/a
Net Income (ttm) -8.19M
Shares Out 13.45M
EPS (ttm) -0.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 14, 2020
Last Price $1.32
Previous Close $1.38
Change ($) -0.06
Change (%) -4.35%
Day's Open 1.37
Day's Range 1.31 - 1.38
Day's Volume 132,911
52-Week Range 1.00 - 3.17

More Stats

Market Cap 17.75M
Enterprise Value 12.80M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 13.45M
Float 8.41M
EPS (basic) -0.79
EPS (diluted) -0.79
FCF / Share -0.61
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 57,747
Short Ratio 0.04
Short % of Float 0.32%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.44
Revenue n/a
Operating Income -8.30M
Net Income -8.19M
Free Cash Flow -6.44M
Net Cash 4.95M
Net Cash / Share 0.37
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -57.61%
ROE -94.73%
ROIC -3,463.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$5.00*
Low
5.00
Current: 1.32
High
5.00
Target: 5.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016
Revenue----
Operating Income-8.24-6.99-1.00-0.41
Net Income-8.59-11.63-1.14-0.42
Shares Outstanding9.854.763.263.26
Earnings Per Share-0.87-2.44-0.35-0.13
Operating Cash Flow-6.34-2.50-0.49-0.27
Free Cash Flow-6.34-2.50-0.49-0.27
Cash & Equivalents6.783.870.020.12
Total Debt--0.690.23
Net Cash / Debt6.783.87-0.67-0.11
Assets7.684.700.030.15
Liabilities0.540.261.030.26
Book Value7.144.44-1.00-0.10
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Adial Pharmaceuticals, Inc.
Country United States
Employees 3
CEO William B. Stilley

Stock Information

Ticker Symbol ADIL
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ADIL
IPO Date July 30, 2018

Description

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. The company was founded in 2010 and is based in Charlottesville, Virginia.